The proposed landmark settlement aims to close a long-running legal battle that has weighed on the New Jersey-based healthcare giant for years, covering approximately 76,000 cases—totalling most of the remaining talc-related claims.
The Settlement Offer
J&J said it will offer up to $3 billion next year, with no additional payments due before 2028. The proposal must be accepted by legal firms representing 95% of the ovarian cancer claims in state and federal courts before it can be finalised.
Erik Haas, the firm's vice president of litigation, said on Monday that the allegations are "meritless" and that J&J was willing to settle in order to finally resolve the matter.
Haas said in a statement that the company is confident that it would have "ultimately prevailed with further litigation" just as it has in the majority of cases heard in court to date. He added that the proposed resolution "allows the company to put this matter behind it" and enable J&J to "remain focused on its mission to develop medicines and devices that save lives."
A Legal Battle Spanning Nearly Two Decades
Lawsuits against J&J over its talc-based baby powder started as early as 2009. The company has faced lawsuits from consumers and their survivors who claim J&J's talc products caused cancer due to contamination with asbestos, a material known to cause cancer.
Talc is a natural mineral made of magnesium, silicon, oxygen and hydrogen, known for its soapy feel and is often used in baby powder. It is mined from the earth and is found in seams close to that of asbestos.
J&J has repeatedly denied the allegations and in its latest announcement said: "Studies show talc is safe, does not contain asbestos and does not cause cancer."
Earlier in July 2026, a federal court handed the firm a victory by questioning individual plaintiffs' ability to show that talc was the direct cause of their ovarian cancer.
The Kenvue Connection
J&J's former consumer health business, Kenvue, holds liability for Johnson's baby powder outside North America. Kenvue—which owns well-known brands including Band-Aid, Listerine, and Calpol—was spun off from J&J in 2022.
A Strategic Shift in Product Portfolio
The settlement offer comes more than two years after J&J ended sales of the talc-based baby powder product in the US. At the time, the company said: "As part of a worldwide portfolio assessment, we have made the commercial decision to transition to an all cornstarch-based baby powder portfolio."
What This Means for African Consumers
While the settlement primarily addresses US lawsuits, the implications extend globally. Johnson & Johnson's baby powder remains widely used across Africa, where regulatory oversight of consumer products can be less stringent than in Western markets.
African consumers who have used J&J's talc-based products may have similar health concerns. However, the legal and regulatory frameworks in most African countries provide limited avenues for consumer redress against multinational corporations.
The settlement also raises questions about product safety standards in African markets. While J&J has transitioned to cornstarch-based formulas in many markets, the company's talc-based products may still be sold in some African countries, and consumers may be unaware of the potential health risks.
Global Implications
The proposed settlement represents a significant moment in product liability law, demonstrating the power of collective legal action against large corporations. It also highlights the importance of regulatory oversight and the need for consumers to be informed about the potential risks associated with widely used products.
Haas emphasised that the proposed resolution "allows the company to put this matter behind it" and enable J&J to "remain focused on its mission to develop medicines and devices that save lives."
With reporting from BBC News, Reuters, AP News, and CNN.
